PATHOPHYSIOLOGICAL SUBSTANTIATION OF THE USE OF A NEW DRUG BASED ON G. LUCIDUM AND ALKHADIA IN THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS COV-2

Authors

  • Pulat M. Abilov
  • Bakhtiyor U. Iriskulov
  • Zukhra N. Boboeva

Keywords:

coronavirus infection, pathogenesis, acute respiratory syndrome, G. lucidum, Alkhadaya

Abstract

The current outbreak of coronavirus disease (COVID-19) is a global emergency as its rapid spread and high mortality rate have caused severe disruption. The number of people infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, is rapidly increasing worldwide. Patients with COVID-19 may develop pneumonia, severe symptoms of acute respiratory distress syndrome (ARDS) and multiple organ failure.

Author Biographies

Pulat M. Abilov

Assistant, basic doctoral student of the Department of Normal and Pathological Physiology of the Tashkent Medical Academy, Uzbekistan

E-mail: pulatabilov1985@mail.ru

Bakhtiyor U. Iriskulov

Professor, MD, Head of the Department of Normal and Pathological Physiology of the Tashkent Medical Academy, Uzbekistan

E-mail: biriskulov@yahoo.com

Zukhra N. Boboeva

PhD, Senior Lecturer, Department of Normal and Pathological Physiology of the
Tashkent Medical Academy, Uzbekistan

E-mail: zukhra1967@mail.ru

Downloads

Published

2022-10-03

How to Cite

Pulat M. Abilov, Bakhtiyor U. Iriskulov, & Zukhra N. Boboeva. (2022). PATHOPHYSIOLOGICAL SUBSTANTIATION OF THE USE OF A NEW DRUG BASED ON G. LUCIDUM AND ALKHADIA IN THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS COV-2. Central Asian Journal of Medicine, (3), 36-44. Retrieved from https://journals.tma.uz/index.php/cajm/article/view/500

Issue

No. 3 (2022): CAJM

Section

Articles